Other equities analysts have also recently issued research reports about the stock. Pacific Crest cut shares of Imperva from an overweight rating to a sector weight rating and lowered their target price for the company from $47.00 to $30.00 in a research note on Tuesday, August 30th. JPMorgan Chase & Co. restated a hold rating on shares of Imperva in a research note on Tuesday, July 12th. Nomura restated a buy rating and set a $55.00 target price (down previously from $60.00) on shares of Imperva in a research note on Friday, July 15th. Imperial Capital restated an outperform rating and set a $50.00 target price (down previously from $55.00) on shares of Imperva in a research note on Monday, August 8th. Finally, Morgan Stanley set a $35.00 target price on shares of Imperva and gave the company a sell rating in a research note on Friday, August 5th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of $52.33.
Imperva (NYSE:IMPV) opened at 49.03 on Friday. The stock’s market cap is $1.60 billion. Imperva has a 52 week low of $31.11 and a 52 week high of $77.99. The company’s 50-day moving average is $48.31 and its 200 day moving average is $44.83.
Imperva (NYSE:IMPV) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by $0.19. Imperva had a negative net margin of 23.75% and a negative return on equity of 25.68%. The firm had revenue of $57.87 million for the quarter, compared to analysts’ expectations of $66.06 million. During the same period last year, the company posted ($0.08) earnings per share. The business’s revenue for the quarter was up 8.2% compared to the same quarter last year. On average, analysts expect that Imperva will post ($0.80) earnings per share for the current fiscal year.
In related news, insider Amichai Shulman sold 938 shares of the firm’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $53.27, for a total value of $49,967.26. Following the completion of the transaction, the insider now directly owns 95,085 shares of the company’s stock, valued at $5,065,177.95. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Mark E. Kraynak sold 5,582 shares of the firm’s stock in a transaction on Friday, September 23rd. The shares were sold at an average price of $51.00, for a total transaction of $284,682.00. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Credit Suisse AG raised its position in Imperva by 865.9% in the second quarter. Credit Suisse AG now owns 1,431,447 shares of the company’s stock worth $61,568,000 after buying an additional 1,283,243 shares during the period. JPMorgan Chase & Co. raised its position in Imperva by 46.8% in the first quarter. JPMorgan Chase & Co. now owns 1,479,012 shares of the company’s stock worth $74,688,000 after buying an additional 471,250 shares during the period. Pictet Asset Management Ltd. raised its position in Imperva by 50.6% in the second quarter. Pictet Asset Management Ltd. now owns 804,552 shares of the company’s stock worth $30,718,000 after buying an additional 270,312 shares during the period. FIL Ltd acquired a new position in Imperva during the second quarter worth $10,170,000. Finally, Jet Capital Investors L P acquired a new position in Imperva during the second quarter worth $9,670,000. 93.26% of the stock is owned by hedge funds and other institutional investors.
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company operates in the segment of development, marketing, sales, service and support of cyber-security solutions that protect business critical data and applications whether in the cloud or on premises.
Receive News & Ratings for Imperva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc. and related companies with MarketBeat.com's FREE daily email newsletter.